TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03604731

Intervention type: DEVICE
Intervention: cytokine adsorbtion during extracorporeal circulation
Description: preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
Study: NCT02908399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIR ONE
Study: NCT03695029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
Study: NCT03168516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
Description: Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
Study: NCT01786317

Intervention type: DEVICE
Intervention: High resolution manometry
Description: Anorectal High resoltion manometry using electronic sensors

Intervention type: DEVICE
Intervention: High resolution manometry
Description: Anorectal High resoltion manometry using electronic sensors
Study: NCT00191854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 150 mg/m2, IV, every 14 days x 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 50 mg/m2, IV, every 14 days x 8 cycles
Study: NCT02815722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
Study: NCT01203644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKY0402
Description: Single dose of SKY0402 administered locally into the surgical wound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
Study: NCT03481179

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical therapy
Description: The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM \& JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM \& JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
Study: NCT04039100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Caregiver Ambassador Support
Description: Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
Study: NCT01239719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone + clemastine
Description: Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.5 mg: 01 tablet every 12 hours.
Study: NCT04321161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicanorm
Description: Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)
Study: NCT03646084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep and Circadian Intervention Program (SCIP) plus rehabilitation program
Description: To study circadian rhythm disorders and sleep disorders and develops the SCIP to improve sleep in the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Rehabilitation program current clinical practice
Study: NCT04041115

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-alcoholic beer
Description: Treatment consisted of 330ml non-alcoholic beer per day, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Treatment consisted of 330ml of water, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
Study: NCT00955773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212 plus everolimus
Description: Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
Study: NCT03026348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine
Study: NCT00955773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212 plus everolimus
Description: Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212 plus everolimus
Description: Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
Study: NCT03118193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olfactive tests
Description: olfactive tests: odor identification, odor discrimination and olfactory threshold

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: one sample of 4mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of faeces
Description: Collection of faeces by patient at home - optional

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Pulsatility imaging
Description: Ultrasound exploration of brain pulsatility - optional
Study: NCT03026348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine
Study: NCT03348436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Study: NCT01394640

Intervention type: BIOLOGICAL
Intervention: Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
Description: The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.

Intervention type: BIOLOGICAL
Intervention: Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
Description: The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
Study: NCT03997292

Intervention type: DRUG
Intervention: Alteplase
Description: According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
Study: NCT01217541

Intervention type: OTHER
Group type: OTHER
Intervention: Education and Supervision
Description: Implementation of Scales in the care of patients with dementia in nursing home units with focus on person-centred care. Supervision of caregivers on a regular basis.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: A control group of nursing home units that do not get any form of active intervention
Study: NCT04389177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Neoadjuvant period:preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks.~Da Vinci robot radical surgery: Before surgery, head/abdomen/chest CT scan, type B ultrasonic, upper gastrointestinal contrast, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 4-6 weeks after last neoadjuvant treatment finished.~Adjuvant period: Adjuvant treatment with pembrolizumab 200mg every 3 weeks (6 cycles) should be performed within 3-6 weeks after surgery if the surgical pathology result is not pCR. abdomen/chest CT scan will be performed every 3 month after surgery.
Study: NCT00234039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT03997292

Intervention type: DRUG
Intervention: Urokinase
Description: 1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
Study: NCT01642745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine (Provocholine)
Description: two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
Study: NCT03284918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol ester

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04595994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
Study: NCT04516395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined antibiotic regimens
Description: Combined antibiotic combinations defined as the optimal antibiotic combination regimens which are created from in vitro study and the application of PK/PD.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard antibiotic regimens
Description: Standard antibiotic regimens defined as the antibiotic regimens which are generally given to the patients following to the hospital protocol.
Study: NCT00864916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Description: Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
Study: NCT03026348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1 Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1 Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1 Adjuvant
Study: NCT00864916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination antiretroviral therapy (cART)
Description: Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
Study: NCT03026348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1 Adjuvant
Study: NCT00864916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo three times per day for 48 weeks.
Study: NCT01642745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol (Aridol)
Description: single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine (Provocholine)
Description: two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
Study: NCT02061319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
Study: NCT00934648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25mg weekly
Study: NCT02149849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified lateral positioning.
Description: Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
Study: NCT02102256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Brainstem Implant
Study: NCT01253811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
Study: NCT00958438

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
Study: NCT02142387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BLS CPR program with dispatcher assisted CPR simulation
Description: the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
Study: NCT01848782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpretation of the abstract of the systematic review

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interpretation of the abstract of the systematic review
Study: NCT02328053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collagen crosslinking group
Description: collagen crosslinking with riboflavin and Ultraviolet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anti-fungal therapy
Description: topical antifungal medications like natamycin eye drops and voriconazole eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical anti-fungal therapy
Description: topical antifungal medications like natamycin eye drops and voriconazole eye drops
Study: NCT04113590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Assisted Transvaginal Cholecystectomy
Description: Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
Study: NCT01695876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 357
Description: Oral administration available in varying dose strength.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AMG 357 containing no active drug
Study: NCT04308031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg [Corlanor]
Description: Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin 0.25 mg
Description: Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)\>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60 Max dose: 0.25 once daily (QD)
Study: NCT01446614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow derived mesenchymal stem cells
Description: Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
Study: NCT02400164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alfapump system
Description: The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
Study: NCT03782831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: intravenous injection every 2 weeks
Study: NCT04095585

Intervention type: GENETIC
Intervention: chromosomal microarray analysis (CMA) and whole exome sequencing (WES)
Description: The investigator evaluated the following hypotheses:~i) atypically large 7q11.23 deletions including additional genes; ii) rare pathogenic variants in genes located within the deletion, in particular GTF2I iii) additional pathogenic copy number variants (CNVs) or rare intragenic pathogenic variants located in other chromosomal regions with various inheritance patterns (autosomal recessive, X-linked, de novo autosomal dominant); given the small number of patients recruited, we focused on rare exonic variants considered to be pathogenic according to the criteria of the American College of Medical Genetics and Genomics (ACMG)
Study: NCT00779259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline 300mg
Description: Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine 648 mg
Description: 648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline 300 mg
Description: Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine 648 mg
Description: 648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.